Insight Molecular Diagnostics

Rising Global Organ Transplants Will Drive Diagnostic Testing Expansion

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

13 Apr 25

Updated

27 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

151.6%

7D

1.7%

Loading

1Y

151.6%

7D

1.7%

You can edit this narrative until Nov 28 4:25 AM. Then, changes will post as Updates.

Author's Valuation

US$712.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 27 Nov 25

Fair value Increased 14%

IMDX: Expanding Clinical Trial Participation Will Drive Market Momentum

Analysts have raised their price target for Insight Molecular Diagnostics from $6.13 to $7.00 per share, citing stronger expected revenue growth and improving profit margins in their updated forecasts. What's in the News Insight Molecular Diagnostics published results showing their GraftAssure assay enabled long-term non-immunosuppressed kidney transplant survival with no rejection, following CD19 CAR-T therapy in a complex patient case (study published in the American Journal of Transplantation).

Shared on 12 Nov 25

Fair value Increased 13%

IMDX: Increased Discount Rate Will Raise Uncertainty for Share Performance

Analysts have raised their price target for Insight Molecular Diagnostics from $5.42 to $6.13, citing improved revenue growth forecasts and higher profit margins as key factors contributing to the increased valuation. What's in the News Insight Molecular Diagnostics published study results in the American Journal of Transplantation, demonstrating the value of its GraftAssure assay for monitoring kidney transplant patients with severe complications.

Shared on 30 Jul 25

Fair value Increased 23%

The consensus analyst price target for Insight Molecular Diagnostics has increased to $5.42, primarily reflecting improved revenue growth forecasts and a rising future P/E multiple. What's in the News The company changed its name from Oncocyte Corporation to Insight Molecular Diagnostics Inc.

Shared on 01 May 25

Fair value Decreased 51%

AnalystConsensusTarget has decreased revenue growth from 91.5% to 29.7%, decreased profit margin from 16.8% to 12.3% and increased future PE multiple from 84.2x to 179.4x.

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Increased 66%

AnalystConsensusTarget has increased revenue growth from 32.1% to 91.5%, increased profit margin from 10.5% to 17.3%, decreased future PE multiple from 244.5x to 81.6x and decreased shares outstanding growth rate from 0.3% to 0.1%.

AnalystConsensusTarget Fair Value

US$7

12.3% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

40.26%

Biotech revenue growth rate

8.93%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.06%

Calculation

US$1.98m

Earnings '28

x

121.65x

PE Ratio '28

=

US$240.46m

Market Cap '28

US$240.46m

Market Cap '28

/

28.86m

No. shares '28

=

US$8.33

Share Price '28

US$8.33 Share Price '28

Discounted to 2025 @ 7.05% p.a.

=

US$6.79

Fair Value '25